NURS 5432 CERTIFICATION SCRIPT 2026
COMPLETE QUESTIONS AND ANSWERS
◉ Hormone Replacement Therapy (HRT).
Answer: Treatment to alleviate menopausal symptoms with
hormones.
◉ Non-hormonal medications.
Answer: Alternatives for managing menopause symptoms without
hormones.
◉ Gabapentin.
Answer: Medication used for hot flashes in menopause.
◉ Clonidine.
Answer: Medication for mild hot flashes, less effective than SSRIs.
◉ Breast cancer risk.
Answer: Increased risk associated with long-term hormone therapy.
◉ VTE.
Answer: Venous thromboembolism, a risk with hormone therapy.
,◉ Short term use.
Answer: Increases CVD, cancer, VTE risks long term.
◉ Tailored therapy.
Answer: Achieve lowest dose for shortest duration.
◉ Menopause onset.
Answer: Introduce therapy early for better risk/benefit.
◉ Absolute contraindications.
Answer: None for hormone replacement therapy.
◉ Estrogen-dependent malignancies.
Answer: Includes breast, ovarian, and uterine cancers.
◉ Unexplained uterine bleeding.
Answer: Requires evaluation before hormone therapy.
◉ History of VTE/CVA.
Answer: Higher estrogen doses cause hypercoagulability.
,◉ Coronary artery disease (CAD).
Answer: Avoid estrogen for cardio-protective benefits.
◉ Active liver disease.
Answer: Higher estrogen doses may induce gallbladder disease.
◉ Genitourinary Syndrome.
Answer: Includes vulvar/vaginal atrophy symptoms.
◉ Topical estrogen therapy.
Answer: Reverses vaginal atrophy, enhances blood flow.
◉ Ospemifene.
Answer: SERM for moderate to severe dyspareunia.
◉ Estrogen and progesterone use.
Answer: Depends on history of hysterectomy.
◉ Fibroadenoma.
Answer: Benign breast mass, smooth and rubbery.
◉ Complex fibroadenoma.
, Answer: Includes cysts >3mm, sclerosing adenosis.
◉ Fine needle aspiration biopsy.
Answer: Used to rule out cancer in masses.
◉ Fibrocystic breast disease.
Answer: Common in premenopausal women, includes cysts.
◉ Nipple discharge.
Answer: Typically benign, requires surgical referral.
◉ Galactorrhea.
Answer: Physiologic discharge; check TSH and prolactin.
◉ Breast cancer risk factors.
Answer: Includes familial link, dense tissue, obesity.
◉ Mammogram screening recommendations.
Answer: USPSTF: 50-74 biennial; ACS: 45 annually.
◉ SERMs.
Answer: Tamoxifen and Raloxifene for breast cancer.
COMPLETE QUESTIONS AND ANSWERS
◉ Hormone Replacement Therapy (HRT).
Answer: Treatment to alleviate menopausal symptoms with
hormones.
◉ Non-hormonal medications.
Answer: Alternatives for managing menopause symptoms without
hormones.
◉ Gabapentin.
Answer: Medication used for hot flashes in menopause.
◉ Clonidine.
Answer: Medication for mild hot flashes, less effective than SSRIs.
◉ Breast cancer risk.
Answer: Increased risk associated with long-term hormone therapy.
◉ VTE.
Answer: Venous thromboembolism, a risk with hormone therapy.
,◉ Short term use.
Answer: Increases CVD, cancer, VTE risks long term.
◉ Tailored therapy.
Answer: Achieve lowest dose for shortest duration.
◉ Menopause onset.
Answer: Introduce therapy early for better risk/benefit.
◉ Absolute contraindications.
Answer: None for hormone replacement therapy.
◉ Estrogen-dependent malignancies.
Answer: Includes breast, ovarian, and uterine cancers.
◉ Unexplained uterine bleeding.
Answer: Requires evaluation before hormone therapy.
◉ History of VTE/CVA.
Answer: Higher estrogen doses cause hypercoagulability.
,◉ Coronary artery disease (CAD).
Answer: Avoid estrogen for cardio-protective benefits.
◉ Active liver disease.
Answer: Higher estrogen doses may induce gallbladder disease.
◉ Genitourinary Syndrome.
Answer: Includes vulvar/vaginal atrophy symptoms.
◉ Topical estrogen therapy.
Answer: Reverses vaginal atrophy, enhances blood flow.
◉ Ospemifene.
Answer: SERM for moderate to severe dyspareunia.
◉ Estrogen and progesterone use.
Answer: Depends on history of hysterectomy.
◉ Fibroadenoma.
Answer: Benign breast mass, smooth and rubbery.
◉ Complex fibroadenoma.
, Answer: Includes cysts >3mm, sclerosing adenosis.
◉ Fine needle aspiration biopsy.
Answer: Used to rule out cancer in masses.
◉ Fibrocystic breast disease.
Answer: Common in premenopausal women, includes cysts.
◉ Nipple discharge.
Answer: Typically benign, requires surgical referral.
◉ Galactorrhea.
Answer: Physiologic discharge; check TSH and prolactin.
◉ Breast cancer risk factors.
Answer: Includes familial link, dense tissue, obesity.
◉ Mammogram screening recommendations.
Answer: USPSTF: 50-74 biennial; ACS: 45 annually.
◉ SERMs.
Answer: Tamoxifen and Raloxifene for breast cancer.
